Effect of Bevacizumab combined with chemotherapy in the treatment of non-small cell lung cancer and its influence on T cell subsets and immune function#br#
PAN Enyuan1 XIA Qin2
1.Department of Pharmacy, Anhui No.2 Provincal People’s Hospital, Anhui Province, Hefei 230041, China;
2.Department of Pharmacy, Ruijin Hospital Affiliated to Medical College of Shanghai Jiao Tong University, Shanghai 200025, China
Abstract：Objective To study the effect of Bevacizumab combined with chemotherapy in the treatment of non-small cell lung cancer (NSCLC) and its influence on T cell subsets and immune function. Methods Eighty NSCLC patients admitted to Anhui No.2 Provincal People’s Hospital from January 2018 to August 2020 were selected as the research subjects, they were divided into observation group and control group by random number table method, with 40 cases in each group. The control group was given Pemetrexed combined with platinum chemotherapy, and the observation group was combined with Bevacizumab on the basis of the chemotherapy. Both groups were given intravenous infusion on the first day, with a cycle of 21 days, and each cycle was given intravenous infusion on the first day for a total of two cycles. The clinical efficacy, the changes of the T cell subsets CD3+, CD4+, CD4+/CD8+, immunoglobulin IgA, IgG, and IgM before and after treatment were compared between the two groups, and the side reaction during the treatment were compared. Results After treatment, the total clinical effective rate of observation group was higher than control group, and the difference was statistically significant (P ＜ 0.05). After treatment, the levels of CD3+, CD4+, CD4+/CD8+, IgA, IgG, and IgM in two groups were lower than those before trentment, and the observation group was higher than the control group, and the differences were statistically significant (P ＜ 0.05). There was no significant difference in the incidence of side reaction between two groups during treatment (P ＞ 0.05). Conclusion Bevacizumab combined with chemotherapy has a significant effect on the treatment of NSCLC patients, which can improve the expression of T cell subsets and immune function, and is worthy of application and promotion.
潘恩媛1 夏琴2. 贝伐珠单抗联合化疗治疗非小细胞肺癌的效果及对T细胞亚群、免疫功能的影响[J]. 中国医药导报, 2021, 18(29): 118-121.
PAN Enyuan1 XIA Qin2. Effect of Bevacizumab combined with chemotherapy in the treatment of non-small cell lung cancer and its influence on T cell subsets and immune function#br#. 中国医药导报, 2021, 18(29): 118-121.
京公网安备 11010502046598号